Tower Research Capital LLC (Trc) Xenon Pharmaceuticals Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,517 shares of XENE stock, worth $61,832. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,517
Previous 5,357
71.68%
Holding current value
$61,832
Previous $167,000
64.07%
% of portfolio
0.0%
Previous 0.0%
Shares
30 transactions
Others Institutions Holding XENE
# of Institutions
240Shares Held
74.2MCall Options Held
235KPut Options Held
271K-
Avoro Capital Advisors LLC New York, NY5.4MShares$220 Million2.96% of portfolio
-
Driehaus Capital Management LLC Chicago, IL4.17MShares$170 Million1.42% of portfolio
-
Janus Henderson Group PLC London, X03.94MShares$161 Million0.08% of portfolio
-
Wellington Management Group LLP Boston, MA3.61MShares$147 Million0.03% of portfolio
-
Braidwell LP Stamford, CT3.61MShares$147 Million8.35% of portfolio
About Xenon Pharmaceuticals Inc.
- Ticker XENE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 62,263,500
- Market Cap $2.54B
- Description
- Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...